Stuart Therapeutics (Stuart) is a clinical stage biopharmaceutical company focused on the development of a unique precision tissue reparative platform for eye diseases called PolyCol. PolyCol is a family of synthesized polypeptide sequences that are specifically designed to repair damaged extracellular matrix (ECM) collagen triple helix structures. These structures play an important role in healthy tissues and are damaged in chronic disease inflammatory processes. Stuart was founded in 2018, and the company was founded to champion a new approach to the treatment of chronic diseases.
Stuart Therapeutics was founded to bring a fresh point of view to the development of therapies for difficult to treat ophthalmic diseases. Our team brings a wide variety of proven clinical, pharmaceutical R&D, operational and partnering skills to support our venture. Our core inventor group identified the promise of PolyCol and has established broad patent coverage to provide the company with an array of options for partnering and internal development. The areas of medicine on which we are focused have affected all of the members of our team, either directly or indirectly. We have a passion for what we do, and a motivation to improve results for patients suffering from these conditions.